MADISON, N.J. (Oct. 4, 2012)- Pfizer Animal Health is seeking research proposals to support the continued study of the clinical efficacy of DRAXXIN® (tulathromycin) Injectable Solution, a macrolide for the treatment of swine respiratory disease (SRD), the leading cause of swine mortality in the U.S.
Pfizer Animal Health will provide up to four grants, $100,000 in total, for clinical research on the use of DRAXXIN as part of an overall disease treatment and control plan that demonstrates a direct benefit to swine health. DRAXXIN will be provided to study investigators at no cost.
“DRAXXIN has consistently proven to be an effective tool in swine health management,” said Shelley Stanford, DVM, MS, MBA, director, U.S. Pork Technical Services at Pfizer. “Through these research grants, we are seeking to further our understanding of DRAXXIN’s real world efficacy and its practical uses.”
The deadline for submission of grant proposals is November 15, 2012. Proposals are only being accepted electronically. All applicants must be current university staff, advanced study students at universities or practicing doctors of veterinary medicine. Proposals will be evaluated on their direct clinical applicability, the potential to enhance the treatment of pigs, relevance to existing scientific knowledge and practical study feasibility.
Complete criteria and proposal requirements can be found at www.pfizerpork.com/draxxin. A Pfizer Animal Health committee will review applications and alert recipients in December 2012.
Approved in the U.S. in 2005, DRAXXIN treats the five most common bacterial causes of SRD, including mycoplasma hyopneumoniae, and controls SRD associated with three bacterial causes in groups of pigs where SRD has been diagnosed. Its one-dose formula provides nine days of extended therapy and effectiveness while minimizing labor. DRAXXIN also helps reduce shedding, which decreases disease transmission and mortality.